• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down 1.5%; Immunovant Shares Spike Higher

    9/26/23 2:26:05 PM ET
    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FEMY alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 400 points on Tuesday.

    The Dow traded down 1.19% to 33,601.60 while the NASDAQ fell 1.48% to 13,074.97. The S&P 500 also fell, dropping, 1.42% to 4,276.00.

    Check This Out: DraftKings To Rally Around 35%? Here Are 10 Other Analyst Forecasts For Tuesday

     

    Leading and Lagging Sectors

    Energy shares fell by just 0.01% on Tuesday.

    In trading on Tuesday, utilities shares tumbled by 2%.

     

    Top Headline

    United Natural Foods Inc (NYSE:UNFI) reported mixed results for its fourth quarter on Tuesday.

    United Natural Foods reported fourth-quarter FY23 sales growth of 2% year-on-year to $7.417 billion, missing the analyst consensus of $7.47 billion. Adjusted EPS of $(0.25) beat the analyst consensus estimate of $(0.28).

    United Natural Foods sees FY24 sales of $30.9 billion-$31.5 billion, against the consensus of $31.03 billion. The company expects FY24 adjusted EPS of $(0.88)-$0.38 versus the consensus of $2.56.

     

    Equities Trading UP

    Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares shot up 442% to $24.01 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.

    Shares of Femasys Inc. (NASDAQ:FEMY) got a boost, shooting 260% to $1.1950 after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube.

    Immunovant, Inc. (NASDAQ:IMVT) shares were also up, gaining 100% to $40.58. Alfasigma agreed to acquire Intercept Pharmaceuticals for $19.00 per share in cash.

     

    Equities Trading DOWN

    TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares dropped 71% to $0.7306 after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.

    Shares of United Natural Foods, Inc. (NYSE:UNFI) were down 25% to $14.18 after the company reported mixed fourth-quarter financial results and issued guidance.

    New Pacific Metals Corp. (NYSE:NEWP) was down, falling 13% to $1.9408. New Pacific Metals announced CAD$35 million bought deal financing.

    Also Check This Out: More Than $8M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

     

    Commodities

    In commodity news, oil traded up 1% to $90.61 while gold traded down 0.9% at $1,920.10.

    Silver traded down 1% to $23.155 on Tuesday while copper fell 0.6% to $3.6475.

     

    Euro zone

    European shares closed mostly lower today. The eurozone’s STOXX 600 fell 0.61% London’s FTSE 100 rose 0.02% while Spain’s IBEX 35 Index fell 0.20% The German DAX fell 0.97% French CAC 40 declined 0.70%, while Italy’s FTSE MIB Index fell 1%.

     

    Asia Pacific Markets

    Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 1.11%, Hong Kong’s Hang Seng Index falling 1.48% and China’s Shanghai Composite Index declining 0.43%. India’s S&P BSE Sensex, meanwhile, slipped 0.1%.

    Hong Kong’s trade deficit increased to $25.6 billion in August from $13.3 billion in the year-ago month. Imports to Hong Kong declined 0.3% year-over-year, while exports from Hong Kong fell 3.7% year-over-year in August.

     

    Economics

    U.S. building permits increased by 6.8% to an annual rate of 1.541 million in August, recording the highest level since October 2022.

    The FHFA house price index rose by 0.8% from the previous month in July versus a revised 0.4% increase in June.

    The S&P CoreLogic Case-Shiller 20-city home price index rose 0.1% year-over-year in July, recording the first rise in five months, versus market expectations for a 0.3% decline.

    Sales of new single-family houses fell by 8.7% to an annualized rate of 675,000 in August.

    The Dallas Fed general business activity index for Texas' service sector fell to a reading of -8.6 in September.

    The manufacturing activity index in the Richmond area climbed to 5 in September versus August’s reading of -7.

    Now Read This: Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,602,110 cases with around 1,176,150 deaths. India confirmed a total of at least 44,998,560 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 695,750,000 cases of COVID-19 worldwide with more than 6,919,470 deaths.

    Get the next $FEMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEMY
    $IMVT
    $NEWP
    $RNAZ

    CompanyDatePrice TargetRatingAnalyst
    United Natural Foods Inc.
    $UNFI
    1/8/2026Hold
    Deutsche Bank
    Immunovant Inc.
    $IMVT
    1/6/2026$50.00Peer Perform → Outperform
    Wolfe Research
    New Pacific Metals Corp.
    $NEWP
    12/5/2025Outperform
    BMO Capital Markets
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    Immunovant Inc.
    $IMVT
    10/14/2025$16.00Hold
    Truist
    Soleno Therapeutics Inc.
    $SLNO
    10/7/2025$125.00Buy
    Goldman
    United Natural Foods Inc.
    $UNFI
    9/25/2025$36.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pappas James C bought $573,000 worth of shares (17,000 units at $33.71) (SEC Form 4)

    4 - UNITED NATURAL FOODS INC (0001020859) (Issuer)

    1/6/26 8:21:40 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    12/12/25 5:17:21 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    1/15/25 4:36:38 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Yen Kristen was granted 10,400 shares, increasing direct ownership by 38% to 37,639 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    1/23/26 6:08:14 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Business Officer Norrett Kevin was granted 3,500 shares, increasing direct ownership by 24% to 17,786 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    1/23/26 6:07:08 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Commercial Officer Manning Meredith was granted 28,600 shares, increasing direct ownership by 66% to 72,029 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    1/23/26 6:06:06 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on United Natural Foods

    Deutsche Bank initiated coverage of United Natural Foods with a rating of Hold

    1/8/26 10:59:33 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    Immunovant Sciences upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Immunovant Sciences from Peer Perform to Outperform and set a new price target of $50.00

    1/6/26 8:39:27 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BMO Capital Markets initiated coverage on New Pacific Metals

    BMO Capital Markets initiated coverage of New Pacific Metals with a rating of Outperform

    12/5/25 8:45:20 AM ET
    $NEWP
    Precious Metals
    Basic Materials

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

    IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway

    2/6/26 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

    BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program's first exp

    2/5/26 8:04:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

    ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women's diagnostic health products. Together with the Company's recent market entry in Spain and the ongoing commercial launch in France, this partnership represents continued execution of Femasys' European

    2/3/26 9:15:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Soleno Therapeutics Inc.

    SCHEDULE 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    2/10/26 11:17:43 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Immunovant Inc.

    10-Q - Immunovant, Inc. (0001764013) (Filer)

    2/6/26 7:24:14 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Immunovant, Inc. (0001764013) (Filer)

    2/6/26 7:16:39 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NEW PACIFIC ANNOUNCES 2025 AGM RESULTS

    VANCOUVER, BC, Nov. 28, 2025 /PRNewswire/ - New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX:NUAG) (NYSE:NEWP) today reported that all matters submitted for approval at New Pacific's annual meeting of shareholders ("AGM") held today as set out in the Company's Notice of Meeting and Management Information Circular, both dated October 24, 2025, were approved by the requisite majority of votes cast at  the AGM.  A total of 144,270,137 common shares, representing 78.53% of the votes attached to all outstanding shares as at the record date for the meeting, were represented at the AGM.  The details of the voting results for the election of directors are set out below: Votes For With

    11/28/25 7:13:00 PM ET
    $NEWP
    Precious Metals
    Basic Materials

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Financials

    Live finance-specific insights

    View All

    Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

    IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway

    2/6/26 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

    DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About ImmunovantImmunovant,

    1/23/26 5:25:47 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    United Natural Foods, Inc. Reports First Quarter Fiscal 2026 Results

    United Natural Foods, Inc. (NYSE:UNFI) (the "Company" or "UNFI") today reported financial results for the first quarter of fiscal 2026 (13 weeks) ended November 1, 2025. First Quarter Fiscal 2026 Performance (comparisons to first quarter fiscal 2025) Net sales decreased 0.4% to $7.8 billion Net loss of $4 million; Loss per diluted share (EPS) of $0.06 Adjusted EBITDA(1) increased 24.6% to $167 million Adjusted EPS(1) increased to $0.56 Net cash used in operating activities of $38 million; Free cash flow(1) used of $54 million Recent Financial and Operational Summary Methodically deploying supply chain solutions and lean to drive continuing customer service improvements; lean

    12/2/25 7:00:00 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    $FEMY
    $IMVT
    $NEWP
    $RNAZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 4:30:58 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

    SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 12:51:18 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care